Role of Val509 in Time-dependent Inhibition of Human Prostaglandin H Synthase-2 Cyclooxygenase Activity by Isoform-selective Agents*

Prostaglandin H synthase (PGHS), a key enzyme in prostanoid biosynthesis, exists as two isoforms. PGHS-1 is considered a basal enzyme; PGHS-2 is associated with inflammation and cell proliferation. A number of highly selective inhibitors for PGHS-2 cyclooxygenase activity are known. Inhibition by these agents involves an initial reversible binding, followed by a time-dependent transition to a much higher affinity enzyme-inhibitor complex, making these agents potent and poorly reversible PGHS-2 inhibitors. To investigate the PGHS-2 structural features that influence the time-dependent action of the selective inhibitors, we have constructed a three-dimensional model of human PGHS-2 by homologous modeling. Examination of the PGHS-2 model identified Val509 as a cyclooxygenase active site residue, that was not conserved in PGHS-1. Recombinant human PGHS-2 with Val509 mutated to either Ile (the corresponding residue in PGHS-1), Ala, Glu, or Lys was expressed by transient transfection of COS-1 cells to evaluate the effects of the mutations on cyclooxygenase activity and on inhibition by four agents reported to be selective for PGHS-2 (NS398, nimesulide, DuP697, and SC58125). All the recombinant proteins were of the expected mass. The mutants exhibited 45-210% of wild-type cyclooxygenase activity, with Km values for arachidonate of 2.1-7.6 μM (wild-type PGHS-2, 3.8 μM), indicating that changes in position 509 had modest effects on cyclooxygenase catalysis. Each of the agents inhibited wild-type PGHS-2 in a time-dependent fashion, and all but nimesulide did the same for the V509A mutant. In contrast, the V509E and V509I PGHS-2 mutants, like recombinant human PGHS-1, did not show time-dependent inhibition with any of the agents, and the V509K mutant responded in a time-dependent manner only to DuP697. Reversible inhibition was still observed with Val509 mutants that did not show time-dependent inhibition. Thus, the side chain structure at position 509 markedly influenced the ability of PGHS-2 to undergo the time-dependent transition without removing inhibitor or substrate binding. These results indicate that Val509 in PGHS-2 has a major role in the structural transition that underlies time-dependent inhibition by the isoform-selective agents.

[1]  J. Falgueyret,et al.  Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety * , 1995, The Journal of Biological Chemistry.

[2]  M. Caton,et al.  PROSTAGLANDINS AND THROMBOXANES , 1977 .

[3]  A. Lesk,et al.  The relation between the divergence of sequence and structure in proteins. , 1986, The EMBO journal.

[4]  D. Galas,et al.  A simple method for site-directed mutagenesis using the polymerase chain reaction. , 1989, Nucleic acids research.

[5]  R. Copeland,et al.  Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Kulmacz.  Topography of prostaglandin H synthase. Antiinflammatory agents and the protease-sensitive arginine 253 region. , 1989, The Journal of biological chemistry.

[7]  William L. Smith,et al.  Involvement of Arginine 120, Glutamate 524, and Tyrosine 355 in the Binding of Arachidonate and 2-Phenylpropionic Acid Inhibitors to the Cyclooxygenase Active Site of Ovine Prostaglandin Endoperoxide H Synthase-1 (*) , 1996, The Journal of Biological Chemistry.

[8]  L. Rome,et al.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Seibert,et al.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Majerus,et al.  Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. , 1977, Prostaglandins.

[11]  R. Kulmacz,et al.  Prostaglandin H synthase-1: evaluation of C-terminus function. , 1995, Archives of biochemistry and biophysics.

[12]  W. Lands,et al.  Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. , 1985, The Journal of biological chemistry.

[13]  K. Landon.  Prostaglandins and Related Substances. A Practical Approach , 1988 .

[14]  W M Barnes,et al.  PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Herschman.  Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[16]  J. Mehta,et al.  Comparison of umbilical vein models for measurement of relative prostacyclin and thromboxane production. , 1982, Prostaglandins.

[17]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[18]  D. Swinney,et al.  The Kinetic Factors That Determine the Affinity and Selectivity for Slow Binding Inhibition of Human Prostaglandin H Synthase 1 and 2 by Indomethacin and Flurbiprofen (*) , 1996, The Journal of Biological Chemistry.

[19]  G. L. Peterson.  [12] Determination of total protein , 1983 .

[20]  C. Benedetto.  Prostaglandins and related substances : a practical approach , 1987 .

[21]  G. Roth,et al.  Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. , 1983, Biochemistry.

[22]  D. Breuer,et al.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1994, The Journal of pharmacology and experimental therapeutics.

[23]  H. Chan,et al.  Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. , 1994, Biochimica et biophysica acta.

[24]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. D. Dyer,et al.  Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. , 1995, Archives of biochemistry and biophysics.

[26]  M. Percival,et al.  Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. , 1995, The Biochemical journal.

[27]  L. Wennogle,et al.  Comparison of recombinant cyclooxygenase‐2 to native isoforms: aspirin labeling of the active site , 1995, FEBS letters.

[28]  M. Percival,et al.  Purification and characterization of recombinant human cyclooxygenase-2. , 1994, Archives of biochemistry and biophysics.

[29]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[30]  Lee-Ho Wang,et al.  Comparison of Hydroperoxide Initiator Requirements for the Cyclooxygenase Activities of Prostaglandin H Synthase-1 and −2 (*) , 1995, The Journal of Biological Chemistry.

[31]  S. Higuchi,et al.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.